Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product: Results From 3 Postmarket Surveillance Studies
| Autor: | Stephen F. Butler, Emily C. McNaughton, Ryan A. Black, Theresa A. Cassidy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Population Poison control Severity of Illness Index 03 medical and health sciences 0302 clinical medicine Abuse liability Prevalence Product Surveillance Postmarketing Medicine Humans Hydromorphone 030212 general & internal medicine Medical prescription education Psychiatry education.field_of_study business.industry medicine.disease Opioid-Related Disorders Poison control center Substance abuse Analgesics Opioid Anesthesiology and Pain Medicine Opioid Delayed-Action Preparations Female Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | The Clinical journal of pain. 34(7) |
| ISSN: | 1536-5409 |
| Popis: | Objective Formulating prescription opioids to limit abuse remains a priority. OROS extended-release (ER) hydromorphone HCl (EXALGO) may have lower abuse potential than many other opioid products. Three postmarketing studies of the relative abuse liability of OROS hydromorphone ER were conducted. Methods Estimates of abuse, unadjusted, and adjusted for prescription volume, were generated for OROS hydromorphone ER and comparators from Q2 2010 through Q2 2014 for a high-risk, substance abuse treatment population and the general population using poison control center data. Comparators were selected for compound, market penetration, and route of administration (ROA) profile. ROA comparisons were made among the substance abuse treatment population. Internet discussion was examined to determine abusers' interest in and desire for the OROS formulation. Results Examination of abuse prevalence among adults within substance abuse treatment, intentional poison exposures, and Internet discussion levels generally support the hypothesis that OROS hydromorphone ER may have lower abuse potential than many other opioid products. OROS hydromorphone ER also seems to be abused less often by alternate ROAs (eg, snorting and injection). Lower levels of online discussion were observed along with relatively low endorsement for abuse. Discussion Abuse of OROS hydromorphone ER was observed in high-risk substance abuse and general population samples but at a very low relative prevalence compared to comparators. Evidence suggests it may be less often abused by alternate ROAs than some comparators. Online data did not find evidence of high levels of desire for OROS hydromorphone ER by recreational abusers. Continued monitoring of this product's abuse liability is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|